

Spiramycin PRODUCT DATA SHEET

issue date 01/06/2020

Product Name: Spiramycin

Product Number: \$007

CAS Number: 8025-81-8

Molecular Formula: Spiramycin I: C₄₃H₇₄N₂O₁₄

Molecular Weight: Spiramycin I: 843.05

Form: Powder

Appearance: White or yellowish powder

Solubility: Methanol: Soluble

Water: Slightly soluble

Source: Streptomyces Ambofaciens

Elemental Analysis: Composition:

Spiramycin I: Not less than 80.0% Spiramycin II: Not more than 5.0% Spiramycin III: Not more than 10.0%

Sum of Spiramycin I, II, III: Not less than 90.0%

pH: 8.5 - 10.5

Optical Rotation: -80.0° to -85.0°

Storage Conditions: 2-8°C

Description: Spiramycin is a broad-spectrum 16-membered ring macrolide antibiotic

composed of a mixture of spiramycin I, II, and III. Spiramycin was first isolated

by PINNERT-SINDICO in 1954 from Streptomyces ambofaciens.

Spiramycin is a bacterial protein synthesis inhibitor, it works by irreversibly binding to the P-site on the 50s ribosome, preventing peptide bond formation and translocation. Spiramycin is effective against gram-negative and gram-

positive bacteria, as well as some Toxoplasma parasites.

Spiramycin has shown anti-obesity effects. In a recent study (2016), it was shown that spiramycin inhibits adipogenesis in 3T3-L1 cells and ameliorates

obesity and associated metabolic indications in HFD-fed mice.

Synonyms: Rovamycine, Formacidine, Foromacidine, NSC 55926,

Kitasamycin

Mechanism of Action: Macrolide antibiotics, like spiramycin, inhibit bacterial growth bacteriostatically

by targeting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. Resistance to spiramycin is commonly attributed to mutations in 50S rRNA preventing spiramycin binding allowing the

cell to synthesize proteins free of error.

Spectrum:

Spiramycin is a broad-spectrum antibiotic targeting a wide range of grampositive and gram-negative bacteria. In addition, spiramycin has demonstrated activity against Toxoplasma parasites.

Microbiology Applications Spiramycin is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against gram positive and gramnegative microbial isolates. Medical microbiologists use AST results to recommend antibiotic treatment options for infected patients. Representative MIC values include:

- Staphylococcus spp. 0.031 μg/mL 0.063 μg/mL
- For a complete list of spiramycin MIC values, click here.

References:

Lovmar, Martin, and Tanel Tenson. "The Mechanism of Action of Macrolides, Lincosamides and Streptogramin B Reveals the Nascent Peptide Exit Path in the Ribosome." Journal of Molecular Microbiology 330.5 (2003): 1005-014.

PINNERT-SINDICO, S., L. Ninet, and J. PREUD. "HOMME & C." COSAR: A new antibiotic-spiramycin. Antibiot. Annual 1955 (1954): 724-727.

Kim MO, Ryu HW, Choi J-H, Son TH, Oh S-R, Lee H-S, et al. (2016) Anti-Obesity Effects of Spiramycin *In Vitro* and *In Vivo*. PLoS ONE 11(7): e0158632. https://doi.org/10.1371/journal.pone.0158632

If you need any help, contact us: info@toku-e.com. Find more information on: www.toku-e.com/